Population PKPD of paclitaxel and carboplatin in ovarian cancer patients: A study by the EORTC‐PAMM‐NDDG

Abstract

These abstracts have been accepted for publication by the Dutch Society of Clinical Pharmacology and BiopharmacyNihon Kohden® and Cambridge Electronic Design (CED®) hardware and Spike2® software at 1 : 35 post drug administration. Results were statistically evaluated using GLM in SPSS® 11.5. Results:Results are presented in table 1. Saccadic peak velocity was increased after MDMA (p = 0.000). Co-administration showed significant increase in peak saccadic velocity compared to placebo (p = 0.004), although significantly less then the increase as observed after MDMA alone (p = 0.003). Smooth pursuit was significantly impaired after ethanol compared to placebo (p = 0.000) and MDMA (p = 0.000), co-adminstration also impaired score compared to placebo (p = 0.000) and MDMA (p = 0.000).Conclusions: MDMA induced arousal as measured by the saccadic peak velocity when administered alone and, to a lesser degree, in combination with ethanol. Co-administration of MDMA with ethanol however could not ameliorate the deterioration of psychomotor accuracy by ethanol as measured by smooth pursuit eye movements. These findings suggest that although MDMA might ameliorate ethanol induced sedation it does not ameliorate impaired psychomotor skills. This might give a false sense of improved performance while intoxicated and thus increases risks of for example road accidents. Introduction: A considerable percentage of young people expose themselves to 3,4-methylenedioxy-methamphetamine (MDMA or 'ecstasy'). Alcohol is relatively commonly used in combination with MDMA (Barrett et al., 2005). As a percentage of MDMA users admit to driving under influence (Riley et al., 2001), the assessment of the effects of co-administration of these substances on psychomotor performance is warranted. Hypothesis:We hypothesized that the co-administration of MDMA and ethanol would ameliorate the impairment induced by ethanol alone. Methods:We performed a double-blind, randomized, placebocontrolled study in 16 healthy volunteers (9 male, 7 female) in the age of 18-29 years. MDMA 100 mg was given orally and blood alcohol concentration (BAC) was maintained at 0.6‰ by a three hour 10% alcohol infusion regime (adjustment of infusion rate according to regular sampled breath alcohol concentration). Saccadic and smooth pursuit eye movements, a validated measure of ethanol induced sedation (van Steveninck et al., 1999), were recorded using Objectives: This study firstly aimed to identify the percentage of nursing home patients who were prescribed more than nine drugs (polypharmacy) and compared prescribing patterns of this patient group to patients who were prescribed fewer drugs. Secondly, teams of hospital pharmacists and nursing home physicians aimed to identify the drug related problems of the polypharmacy patients and the extent to which it was feasible to optimise their medication profiles.Methods: Characteristics of the polypharmacy population were illustrated by retrospective point measurements in five Dutch nursing homes (total of 742 beds) over the years ...

Optimizing Therapeutic Drug Monitoring in Pregnant Women: A Critical Literature Review

“…Although these changes were larger (>20%) for docetaxel, paclitaxel, dacarbazine, and carboplatin, suggesting that dose adjustment is necessary, the TDM of oncological drugs is generally related to the maximum tolerated dose. 138,143,144…”

“…Although these changes were larger (.20%) for docetaxel, paclitaxel, dacarbazine, and carboplatin, suggesting that dose adjustment is necessary, the TDM of oncological drugs is generally related to the maximum tolerated dose. 138,143,144 Furthermore, these conclusions are based on scarce data with a small number of pregnant women investigated; thus, further research is necessary to confirmation of this information.…”

A Phase I and Pharmacokinetic Study of Weekly Oxaliplatin Followed by Paclitaxel in Patients with Solid Tumors

“…A similar approach has been used for studying the clinical pharmacokinetics of carboplatin (36). This approach has several advantages over the conventional approach of averaging individual pharmacokinetic variables: (a) it better defines the values of population pharmacokinetic variables, (b) it provides a better estimation of the interpatient variability of these variables, and (c) it defines a quantitative relationship between the covariate effect and pharmacokinetic variables (37).…”